Literature DB >> 28752619

Spectrum and immunophenotyping of 653 patients with B-cell chronic lymphoproliferative disorders in China: A single-centre analysis.

Yi Miao1, Lei Cao1, Qian Sun1, Xiao-Tong Li1, Yan Wang1, Chun Qiao1, Li Wang1, Rong Wang1, Hai-Rong Qiu1, Wei Xu1, Jian-Yong Li1,2, Yu-Jie Wu1, Lei Fan1.   

Abstract

The incidence of B-cell chronic lymphoproliferative disorders (B-CLPDs) is significantly lower in China than that in western countries. There have been studies involving small cohorts with conflicting results regarding the spectrum of B-CLPDs in China, and the types and immunophenotyping of B-CLPDs in China remain largely unexplored. We conducted a retrospective analysis of 653 cases of B-CLPDs seen in our centre from 2011 to 2015. Four-colour flow cytometry was used to determine the expression of each immunological marker, and the diagnostic values of the immunological markers were also investigated. Chronic lymphocytic leukaemia (CLL) was the most common type of B-CLPD, which was consistent with that in west countries. However, the proportions of CLL (55.9%), follicular lymphoma (2.6%), and hairy cell leukaemia (0.2%) were lower, while the proportion of lymphoplasmacytic lymphoma/WaldenstrÖm macroglobulinaemia (5.4%) was higher in China, as compared with western countries. With respect to immunophenotypic characteristics, CD23 (31.7%) was more frequently expressed in mantle cell lymphoma (MCL) in our cohort than that in western countries. Immunophenotyping was useful in differentiating MCL from CLL or B-cell prolymphocytic leukaemia and lymphoplasmacytic lymphoma/WaldenstrÖm macroglobulinaemia from splenic marginal zone lymphoma. CD200 was of better diagnostic performance (accuracy: 94.6%) in differentiating CLL from MCL compared with CD23 (accuracy: 93.3%). Some cases of B-CPLDs, however, had no definite diagnoses, which were diagnosed as CD5+ B-CPLDs unclassified (7.7%) and CD5- B-CPLDs unclassified (15.8%). This is the largest study that systematically explores the spectrum and immunophenotyping of B-CLPDs in Asia, confirming that spectrum of B-CLPDs in China was different from that in western countries. The immunophenotypic features of B-CLPDs were similar between China and western countries, although a few disparities exist. Cases with no definite diagnoses warrant further studies in the future.
Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  B-cell chronic lymphoproliferative disorders; chronic lymphocytic leukaemia; flow cytometry; immunophenotyping; spectrum

Mesh:

Year:  2017        PMID: 28752619     DOI: 10.1002/hon.2461

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  5 in total

Review 1.  CD200 and Chronic Lymphocytic Leukemia: Biological and Clinical Relevance.

Authors:  Giovanni D'Arena; Vincenzo De Feo; Giuseppe Pietrantuono; Elisa Seneca; Giovanna Mansueto; Oreste Villani; Francesco La Rocca; Fiorella D'Auria; Teodora Statuto; Luciana Valvano; Francesca Arruga; Silvia Deaglio; Dimitar G Efremov; Alessandro Sgambato; Luca Laurenti
Journal:  Front Oncol       Date:  2020-11-26       Impact factor: 6.244

2.  Sustained Remission of Relapsed or Refractory Mantle Cell Lymphoma After 4-1BB-Based CD19-Directed CAR-T Therapy.

Authors:  Chunmei Yang; Wen Lei; Hongqiong Xie; Gongqiang Wu; Juying Wei; Aibin Liang; Wenbin Qian
Journal:  Onco Targets Ther       Date:  2020-11-25       Impact factor: 4.147

3.  [The consensus for differential diagnosis of B cell chronic lymphoproliferative diseases in China (2018 edition)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2018-05-14

Review 4.  Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group.

Authors:  Dok Hyun Yoon; Junning Cao; Tsai-Yun Chen; Koji Izutsu; Seok Jin Kim; Yok Lam Kwong; Tong Yu Lin; Lim Soon Thye; Bing Xu; Deok Hwan Yang; Won Seog Kim
Journal:  J Hematol Oncol       Date:  2020-03-17       Impact factor: 17.388

5.  Screening for monoclonal B-lymphocyte expansion in a hospital-based Chinese population with lymphocytosis: an observational cohort study.

Authors:  Jiadai Xu; Jing Li; Zheng Wei; Yue Wang; Peng Liu
Journal:  BMJ Open       Date:  2020-09-15       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.